Francisco J. Hernandez-Ilizaliturri MD

Francisco Hernandez-Ilizaliturri

Francisco J. Hernandez-Ilizaliturri
MD

Clinical Associate Professor of Medicine

Department of Medicine

Jacobs School of Medicine & Biomedical Sciences


Specialty/Research Focus

Internal Medicine; Medical Oncology

Contact Information
Roswell Park Cancer Institute
Carlton & Elm Streets
Buffalo, New York 14263
Phone: (716) 845-1359
fh3@buffalo.edu



Education and Training:

  • Fellowship, Medicine & Immunology, Roswell Park Cancer Institute (2003)
  • Fellowship, Medical Oncology, University at Buffalo/Roswell Park Cancer Institute (2002)
  • Residency, Internal Medicine, University at Buffalo/Millard Fillmore Hospitals (1999)
  • Residency, Internal Medicine, Instituto Medico del Seguro Social (1996)
  • MD, Internal Medicine, The Instituto Tecnologico y de Estudios Superiores de Monterrey (1995)

Employment:

  • Clinical Associate Professor, Medicine, Roswell Park Comprehensive Cancer Center Jacobs School of Medicine & Biomedical Sciences (2016-present)
  • Assistant Professor of Immunology, Medicine, University at Buffalo/Roswell Park Cancer Institute Jacobs School of Medicine & Biomedical Sciences (2006-present)
  • Assistant Professor of Medicine, Medicine, University at Buffalo, The State University of New York Jacobs School of Medicine & Biomedical Sciences (2004-present)
  • Assistant Professor of Medicine, Medicine, Roswell Park Cancer Institute/University at Buffalo (2003-present)
  • Member, Tumor Immunology Program, Roswell Park Cancer Institute (2003–2006)
  • Physician Scientist, Roswell Park Cancer Institute (2002–2003)

Awards and Honors:

  • Patient Service Award, Leukemia & Lymphoma Society (2011)
  • Best Scientific Report, Roswell Park Cancer Institute (2002)
  • Award of Excellence Scholarly Exchange Day, University at Buffalo (2002)
  • Honorable Mention in Medicine, Instituto Tecnologico y de Estudios Superior (1995)

Grants and Sponsored Research:

  • July 2013–June 2017
    Targeting the P13K/Akt Pathway in Therapy Resistant B-cell NHL
    St. Baldricks Foundation
    Role: Consultant
    $445,000
  • July 2015–June 2016
    Targeted Therapy in Resistant B-NHL
    National Cancer Institute
    Role: Consultant
  • July 2014–June 2015
    Targeted Therapies in B-NHL
    National Cancer Institute
    Role: Consultant
  • June 2009–May 2014
    Targeting the proteasome to overcome therapy resistance in B-NHL.
    NIH
    Role: Co-Investigator
  • March 2011–March 2012
    Lymphoma translational research infrastructure.
    JPWCC / RPCI
    Role: Principal Investigator

Journal Articles:

See all (5 more)

Abstracts:

  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Activity of Ofatumumab (OFA), a Fully Human Monoclonal Antibody Targeting CD20, Against Rituximab (RTX)-Sensitive (RSCL) and Rituximab-Resistant Cell Lines (RRCL), In Vivo, and Primary Tumor Cells Derived from Patients with B-Cell Lymphoma. (May) 8095-8095
  • Barth MJ, Pendurti G, Mavis C, Czuczman NM, Gibbs JF, Deeb G, Czuczman MS, Hernandez-Ilizaliturri FJ. (2011) Activity of Rituximab and Ofatumumab Against Mantle Cell Lymphoma (MCL) in Vitro in MCL Cell Lines and Ex Vivo in Tumor Cells Derived From Patient Tumor Samples. (Nov) 4972-4972
  • Frys S, Barth MJ, Gu J, Mavis C, Gibbs JF, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Etinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor is Active in B-Cell Lymphoma Pre-Clinical Models and Enhances the Anti-Tumor Activity of Rituximab, Chemotherapy Agents and Proteasome Inhibitors. (Nov) 1649-1649
  • Dawar R, Barth MJ, Mavis C, Skitzki J, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. (2012) Evaluation of MLN4924, an Investigational NEDD8-Activating Enzyme (NAE) Inhibitor, as a Novel Targeted Agent with Single-Agent Antitumor Activity in Mantle Cell Lymphoma (MCL) and Hodgkin Lymphoma Pre-Clinical Models. (May)
  • Czuczman NM, Barth MJ, Dawar R, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Evaluation of the Anti-Tumor Activity of MLN4924 (a Novel NEDD8 Activating Enzyme Inhibitor) in Pre-Clinical Models of Rituximab Chemotherapy-Sensitive or -Resistant B-Cell Lymphoma. (Nov) 2761-2761
  • Barth MJ, Mavis C, Czuczman NM, Frys S, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2013) MLN4924, An Investigational Inhibitor Of NEDD8 Activating Enzyme (NAE), Is Active In Mantle Cell Lymphoma (MCL) Pre-Clinical Models and Enhances Rituximab Activity In Vivo. (Dec) 647-647
  • Barth MJ, Mavis C, Hernandez-Ilizaliturri FJ, Czuczman MS. (2012) MLN4924, an Investigational Small Molecule Inhibitor of NEDD8-Activating Enzyme (NAE), Inhibits NF-kB Activity and Induces G1 Cell Cycle Arrest and Apoptosis in Pre-Clinical Models of Hodgkin Lymphoma (HL). (Nov) 3717-3717
  • Barth MJ, Pendurti G, Tsai P, Mavis C, Klener P, Czuczman MS, Hernandez-Ilizaliturri FJ. (2012) Ofatumumab (OFA) is a Novel Anti-CD20 Monoclonal Antibody (mAb) with Improved Anti-Tumor Activity In Vitro and In Vivo in Mantle Cell Lymphoma (MCL) Pre-Clinical Models. (Nov) 2757-2757
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents In Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. (Nov) 3917-3917
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. (2010) Ofatumumab, a Fully Human Monoclonal Antibody Targeting CD20, Demonstrates Activity Against and Potentiates the Anti-Tumor Activity of Chemotherapy Agents in Rituximab-Sensitive Cell Lines (RSCL), Rituximab-Resistant Cell Lines (RRCL), Lymphoma Xenograft. (Nov)
  • Frys S, Skomra A, Czuczman NM, Mavis C, Rolland D, Lim M, Tiwari A, Cairo MS, Czuczman MS, Hernandez-Ilizaliturri FJ, Barth MJ. (2013) The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models. (Dec) 5144-5144
  • Miller J, Barth MJ, Mavis C, Tsai P, Klener P, Hernandez-Ilizaliturri FJ, Czuczman MS. (2012) Ublituximab (TGTX-1101), a Novel Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Activity in Rituximab-Sensitive and Rituximab-Resistant B Non-Hodgkin Lymphoma (B-NHL) Pre-Clinical In Vitro and In Vivo Models. (Nov) 2756-2756
See all (2 more)

Professional Memberships:

  • American Association for Cancer Research Member (2003–present)
  • American Society of Hematology (2001–present)
  • American Society of Clinical Oncology (1999–present)
  • American College of Physicians (1996–1999)
  • American Medical Association (1996–1999)

School News:

In the Media:


Clinical Specialties:

Clinical Offices:

Insurance Accepted:



Contact Information

Roswell Park Cancer Institute
Carlton & Elm Streets
Buffalo, New York 14263
Phone: (716) 845-1359
fh3@buffalo.edu